Matthew Hoffmann
About Matthew Hoffmann
Matthew Hoffmann is the Director of DMPK at Bristol-Myers Squibb with over 20 years of experience in drug metabolism and pharmacokinetics.
Current Position at Bristol-Myers Squibb
Matthew Hoffmann currently holds the position of Director, DMPK at Bristol-Myers Squibb. Since November 2019, he has been leading the Drug Metabolism Laboratory. His role focuses on overseeing the drug metabolism and pharmacokinetics (DMPK) aspects of pharmaceutical research and development. Hoffmann utilizes his extensive experience in the field to contribute to the company's efforts in drug discovery and safety evaluation.
Previous Role at Celgene
Before joining Bristol-Myers Squibb, Matthew Hoffmann worked at Celgene for a decade, from 2009 to 2019. At Celgene, he served as Director, DMPK. In this role, he was responsible for directing drug metabolism and pharmacokinetics studies to support drug development projects. His tenure at Celgene was marked by significant contributions to the company’s therapeutic advancements.
Career at Wyeth Research
Prior to his role at Celgene, Matthew Hoffmann spent nearly nine years with Wyeth Research, from 2000 to 2009. He held the position of Section Head, focusing on drug metabolism. During his time at Wyeth Research, Hoffmann worked on various projects related to drug safety and efficacy, leveraging his expertise in toxicology and metabolism to enhance the company's research output.
Educational Background
Matthew Hoffmann has an extensive educational background in the fields of biology and toxicology. He earned his PhD in Toxicology and Drug Metabolism from Rutgers University, where he studied from 1995 to 2000. Prior to that, he completed his undergraduate studies at Cornell University, obtaining a Bachelor of Science in Biology from 1991 to 1995. His academic training provided a solid foundation for his career in drug metabolism and pharmacokinetics.
Expertise in Drug Metabolism and Pharmacokinetics
With over 20 years of experience in the industry, Matthew Hoffmann is an expert in drug metabolism and pharmacokinetics (DMPK). His career has spanned significant roles at top pharmaceutical companies, including Bristol-Myers Squibb, Celgene, and Wyeth Research. Hoffmann’s expertise includes directing DMPK studies, toxicological assessments, and leading research teams. His in-depth knowledge and extensive experience have made him a key contributor to advancements in pharmaceutical research and development.